Cortagen: why there is so little to say about it

Cortagen is sold as a brain peptide, but there is very little research behind it. A PubMed search in September 2026 returned 15 records that mention it [7]. Most come from the St Petersburg group that designed it or its collaborators, almost all are in rats, mice or cells, and none is a trial in people. This guide is shorter than usual because the evidence is.

What it is

Cortagen is a tetrapeptide: alanine, glutamic acid, aspartic acid and proline (AEDP). Researchers linked to Vladimir Khavinson’s Institute of Bioregulation and Gerontology in St Petersburg designed it from the amino-acid make-up of Cortexin, a polypeptide extract of animal brain cortex used in clinics [3,5]. It belongs to the same family of “peptide bioregulators” as epitalon (AEDG), which differs from it by a single amino acid. The theory behind the family is that very short peptides can enter cells and adjust gene activity in the tissue they came from. That remains a hypothesis from one research school.

Don’t confuse cortagen with Cortexin itself. Cortexin is a mixture with its own, separate literature; cortagen is a single synthetic molecule. Some online sources cite Cortexin studies as if they were cortagen evidence.

The human evidence

We found none. There is no published clinical trial of cortagen in any indexed journal, and no registered trial.

One 2004 abstract states that in humans cortagen showed “a pronounced therapeutic effect” on recovery of injured peripheral nerves [3]. It gives no reference, numbers or study details, and we could not find the study it refers to. Treat it as an unsupported claim.

The only work involving human material we found is a lab study: white blood cells taken from people aged 75 to 88 were exposed to several short peptides, including cortagen, and all of them loosened tightly packed chromatin, the way DNA is stored in the nucleus [6]. That is a test-tube finding about gene packaging. It says nothing about effects in a living person.

What the animal work shows

Nerve regeneration in rats

The clearest numbers come from the earliest study. Rats had their sciatic nerve cut and stitched, then received 10 micrograms per kg of cortagen by injection daily for 10 days [1]. Compared with controls, regenerating nerve fibres grew 27% faster and conducted signals 40% faster [1]. A follow-up from the same group reported that the benefit to nerve function persisted after dosing stopped, but its English abstract gives no figures [2].

Brain and behaviour

• Chronic brain ischaemia in rats. Cortexin and cortagen both sped up recovery of disturbed behaviour and limited oxidative damage in brain tissue [4]. The paper is in Russian, and the English abstract has no numbers.
• Behaviour in mice. The closest thing to outside work is a 2009 study led from Italy’s national health institute, with one co-author from Geropharm, a St Petersburg pharmaceutical company [5]. In mice, one cortagen dose (0.03 mg/kg) increased movement both after one dose and after five days. After five days of dosing, though, the other two doses, and the Cortexin reference dose, produced anxiety-like behaviour in the maze test [5]. That is a mixed result, and it is sometimes summarised online as cortagen being free of anxiety effects.
• Gene activity in mouse hearts. Five days of cortagen injections in mice changed the activity of 234 gene clones, matching 110 known genes, out of more than 15,000 measured [3]. That shows the peptide reaches tissue and has some effect there. It doesn’t show benefit, and the organ studied was the heart, not the brain.

Reading the claims you’ll see

Product pages for cortagen tend to list memory, focus, nerve repair and brain protection. Put each claim next to the studies above and it maps to a single rodent study, usually from one group, usually reported in a short abstract without numbers. The nerve-repair claim traces back to rats with a cut sciatic nerve [1]. The brain-protection claim traces to rats with reduced blood flow to the brain [4]. We found no study of memory or focus in any species that tested cortagen on its own.

Safety and side effects reported

There are no human safety data. The animal papers don’t report toxicity, but they weren’t designed as safety studies and most report no figures on adverse effects. The mouse behaviour study’s finding of anxiety-like behaviour after repeated dosing at some doses is the only signal of an unwanted effect we found [5].

Legal and regulatory status

Cortagen is not approved as a medicine in the UK, the US or the EU. It is sold online as a research chemical. It isn’t named on the WADA Prohibited List, but as a substance with no approval for human use it would fall under WADA’s S0 category for athletes.

What we still don’t know

Nearly everything that matters: whether it does anything in people, at what dose, how it is absorbed and cleared, what side effects it has, and whether the nerve results in rats would repeat in any lab outside the group that designed it.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.